Patent 8962650 was granted and assigned to Eisai on February, 2015 by the United States Patent and Trademark Office.
A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II):